EOM Acceptance: What’s Next?

John Elliott from Carevive extends warm congratulations to oncology sites, cancer centers, and programs that have applied for the Enhancing Oncology Model (EOM). CMS has started sending acceptance letters, and it’s time to gear up for what’s next.

Step one is to acknowledge the acceptance confirmation to ensure a smooth setup for the July start of the EOM. Step two involves referencing an email received during the week of January 16th, containing benchmarking calculations. Understanding these benchmarks is crucial for anticipating reimbursements based on historical patient volumes and episodes.

Lastly, step three involves preparing a well-thought-out plan for July 1st, focusing on practice redesign activities. This includes coordinating human resources, embracing health equity components, integrating ePROs, and optimizing technology for efficiency and success in the model.

Congratulations to those accepted, and if you’re still awaiting news, don’t hesitate to reach out to Carevive for guidance on navigating these exciting next steps.

Recent Episodes

In this episode of Inside Restoration & Recovery, host Martha Lewis welcomes Jason McClaren, Director of Facilities Operations at Reunion Rehabilitation Hospitals, to discuss the critical advantage of partnering with a restoration team experienced in healthcare. A former firefighter and military veteran, Jason has spent the last decade managing safety, risk, and emergency preparedness…

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…